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Objectives The purpose of the study was to evaluate the efficacy and safety of the entirely subcutaneous implantable
cardioverter-defibrillator (S-ICD).
Background A new entirely S-ICD has been introduced, that does not require lead placement in or on the heart. The authors
report the largest multicenter experience to date with the S-ICD with a minimum of 1-year follow-up in the first
118 Dutch patients who were implanted with this device.
Methods Patients were selected if they had a class I or IIa indication for primary or secondary prevention of sudden car-
diac death. All consecutive patients from 4 high-volume centers in the Netherlands with an S-ICD implanted be-
tween December 2008 and April 2011 were included.
Results A total of 118 patients (75% males, mean age 50 years) received the S-ICD. After 18 months of follow-up, 8 pa-
tients experienced 45 successful appropriate shocks (98% first shock conversion efficacy). No sudden deaths
occurred. Fifteen patients (13%) received inappropriate shocks, mainly due to T-wave oversensing, which was
mostly solved by a software upgrade and changing the sensing vector of the S-ICD. Sixteen patients (14%) expe-
rienced complications. Adverse events were more frequent in the first 15 implantations per center compared
with subsequent implantations (inappropriate shocks 19% vs. 6.7%, p  0.03; complications 17% vs. 10%,
p  0.10).
Conclusions This study demonstrates that the S-ICD is effective in terminating ventricular arrhythmias. There is, however, a
considerable percentage of ICD related adverse events, which decreases as the therapy evolves and experience
increases. (J Am Coll Cardiol 2012;60:1933–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.053Implantable cardioverter-defibrillators (ICDs) are widely
used to prevent fatal outcomes associated with life-
threatening arrhythmic episodes in a variety of cardiac
diseases (1–4). Traditionally, ICDs have been implanted
transvenously by creating a pocket in the subclavicular area
and gaining vascular access to reach the heart. This ap-
proach, although considered the standard of care for pacing
and ICD therapy, has its drawbacks, such as short- and
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ciated with obtaining venous access. This can prolong the
procedure and occasionally results in failed ICD implanta-
tion. Also, in case of device infection, the presence of
intracardiac leads is a risk for endocarditis, which can lead to
major morbidity and mortality (5). Additionally, implanted
transvenous leads are subject to mechanical stress associated
with heart motion, body motion, and patient anatomy. This
can influence lead longevity. Lead fractures and inside-out
abrasions in commonly used leads such as Sprint Fidelis
(Medtronic Inc., Minneapolis, Minnesota) and Riata dem-
onstrate that even modern leads are susceptible to lead
failure. Clinical management in these patients is difficult
and potentially harmful (6,7). Lead failure either generates
inappropriate shocks or impedes appropriate therapy.
Therefore, despite decades of innovations in lead design,
lead complications (e.g., lead dislodgement, lead fracture,
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limitation in the use of trans-
venous ICDs (TV-ICD). A dif-
ferent approach to ICD implan-
tation might alleviate these
concerns.
Recently, a new subcutaneous
ICD (S-ICD) was introduced in
Europe (8). The S-ICD is
unique in that its implantation is
entirely subcutaneous, eliminat-
ing the need for lead placement
in or on the heart and simplifying
the implant procedure by using
anatomical landmarks instead of
fluoroscopy imaging. We report
the burgeoning and largest expe-
rience to date with the S-ICD
with a minimum of 1-year
follow-up in the first 118 pa-
tients who were treated with this novel technology in the
Netherlands.
Method
Study design. This study was conducted in 4 high-volume
ICD-implanting hospitals in the Netherlands. The study
was performed using routine files of consecutive patients
implanted with an S-ICD. All patients were aware of the
innovative aspects, limitations, and potential advantages and
disadvantages of the device. Patients who had an S-ICD
implanted prior to the CE approval provided written in-
formed consent and the use of the device was approved by
the Medical Ethical Committee. Permission of the Medical
Ethical Committee was not required for retrospective anal-
ysis of stored data.
Study population. Patients were eligible for an S-ICD if
they had a class I or IIa ICD indication for ICD therapy
according to the American Heart Association/American
College of Cardiology/European Society of Cardiology
2006 guidelines (9) for primary or secondary prevention of
sudden cardiac death. Patients with an indication for bra-
dycardia or antitachycardia pacing (ATP) or resynchroniza-
tion therapy were not considered for S-ICD implantation.
Patients were selected for S-ICD implantation by 3 criteria:
1) patient preference; 2) after complications of a transvenous
system that made reimplantation of a TV-ICD unattractive;
and 3) when the physician deemed S-ICD implantation
more appropriate than a transvenous system (e.g., because of
a young age of the patient). Forty patients have been
previously reported (8,10). Patients included in the IDE
(Investigational Device Exemption) Clinical Study
(NCT01064076) or PRAETORIAN (Prospective, RAn-
domizEd comparison of subcuTaneOus and tRansvenous
ImplANtable cardioverter-defibrillator therapy) trial
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
mVT  monomorphic
ventricular tachycardia
S-ICD  subcutaneous
implantable
cardioverter-defibrillator
TV-ICD  transvenous
implantable
cardioverter-defibrillator
VF  ventricular fibrillation
VT  ventricular
tachycardia(NCT01296022) (11) were left out from our analysis. 2T-waveform analysis using the customized measurement
screening tool was performed and deemed acceptable in all
patients. All patients were implanted between December 2008
and April 2011.
Implantation. The S-ICD (Cameron Health S-ICD Sys-
tem, Cameron Health, San Clemente, California) consists
of 3 components: the SQ-RX Pulse Generator, the
Q-TRAK Subcutaneous Electrode, and the Q-TECH
Programmer. Antibiotic prophylaxis consisted of intrave-
nous flucloxacillin (1,000 or 3,000 mg) or cephazoline
(1,000 or 2,000 mg) given before the procedure. General
anesthesia or local anesthesia in combination with conscious
sedation was used. The S-ICD was implanted without
fluoroscopy using anatomical landmarks only. An additional
suture sleeve at xiphoid position was used from September
2009 after the first 20 patients in this study. Due to a
relative high incidence of inappropriate shocks in the earlier
implanted S-ICD patients (8), a software upgrade was
applied to all devices since October 2009. This software
upgrade was designed to decrease oversensing by adjusting
the detection profiles of the system in the conditional zone
to allow for a slightly longer refractory period. At least 1
defibrillation testing was done with 65 J in all patients.
Polarity was reversed in case of failure. After implantation a
chest x-ray was performed to check correct positioning of
the ICD and subcutaneous lead. Patients were mobilized
immediately after the procedure. Most patients were dis-
charged on the day of the procedure or on the following day.
Device programming. Most device settings in the S-ICD
are automated. The device has 3 sensing vectors, and will
automatically select the optimal vector during implantation.
Thereafter, a template is made to store the QRS morphol-
ogy, referred to as an automatic setup. A conditional
discrimination zone incorporating a feature-extraction tech-
nique was programmed between rates of 170 and 250
beats/min to distinguish supraventricular tachycardia from
ventricular tachycardia (VT). Shock therapy was pro-
grammed at maximum output (80 J), with potential trans-
thoracic post-shock pacing therapy for 30 s.
Follow-up. All patients visited the ICD outpatient clinic at
least within 2 months after implantation. Thereafter pa-
tients were evaluated at the outpatient clinic at intervals of
6 months. Additional follow-up visits took place on indi-
cation, for instance after shock therapy or complications.
Careful history taking was done and all arrhythmic events
were routinely examined every visit in the follow-up period.
Statistical analysis. Categorical data are displayed as per-
centages. Continuous data are described as mean  SD. To
ompare the inappropriate shock and complication rate
etween first and later implants Fisher’s exact test was used.
e considered p values 0.05 statistically significant.
esults
atient characteristics. From December 2008 to April
011 of the approximately 1,300 patients who had a ICD
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pacing, 118 patients (9%) were selected and received an
S-ICD. Patient characteristics are displayed in Table 1. The
largest subgroup of patients was diagnosed with ischemic
cardiomyopathy (n  45 [38%]) and 27 patients (23%)
received an ICD because of an inherited cardiac disease.
More than half of the patients (n  71 [60%]) received an
ICD for primary prevention, of whom 24 patients (mean
left ventricular ejection fraction [LVEF] of 56%) had an
inherited arrhythmia syndrome. There were 6 patients with
a secondary prevention indication because of monomorphic
Patient Characteristics ofs Implanted With an S-ICD (n  118)Table 1 Pa i nt Char cteristics ofPatients Implanted With an S-ICD (n  118)
Male 89 (75)
Age at implant, yrs 50 14
Clinical disease
Ischemic cardiomyopathy (n  118)* 45 (38)
Dilated cardiomyopathy (n  118)* 22 (19)
Nonischemic/nondilated cardiomyopathy (n  118)* 8 (6.8)
Inherited cardiac disease (n  118)* 27 (23)
Congenital heart disease (n  118)* 1 (0.8)
Idiopathic VF (n  118)* 15 (13)
Other cardiac history
Hypertension (n  117)* 14 (12)
Diabetes mellitus (n  117)* 14 (12)
Atrial fibrillation (n  118)* 13 (11)
Moderate/severe valvulopathy (n  84)* 11 (13)
Previous CABG (n  118)* 11 (9.3)
Nonsustained VTs (n  116)* 24 (21)
ECG
PR interval, ms) 170 29
PR interval 200 (n  118)* 13 (11)
QRS interval, ms 102 17
QRS interval 120 (n  118)* 11 (9.3)
LVEF 41 15
Primary prevention 38 12
Secondary prevention 50 14
NYHA functional class
I (n  114)* 86 (75)
II (n  114)* 23 (20)
III (n  114)* 5 (4.4)
IV (n  114)* 0 (0.0)
Medication
Beta-blocker (n  117)* 71 (61)
ACE inhibitor/ARB (n  117)* 58 (50)
Oral anticoagulants (n  56)* 22 (39)
ICD indication
Primary (n  118)* 71 (60)
Secondary
VF in history (n  118)* 39 (33)
Polymorphic VT in history (n  118)* 2 (1.7)
Monomorphic VT in history (n  118)* 6 (5.1)
Values are n (%) or mean  SD. *Number of persons for whom there were available data.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary
rtery bypass graft; ECG electrocardiogram; ICD implantable cardioverter-defibrillator; LVEF
eft ventricular ejection fraction; NYHA  New York Heart Association; S-ICD  subcutaneous
mplantable cardioverter-defibrillator; VF  ventricular fibrillation; VT  ventricular tachycardia.VT (mVT). The mean LVEF was 41% (38% in patientswith S-ICDs implanted for primary prevention, 50% for
secondary prevention). The mean age at implantation was
50 years (range 10 to 83 years). Thirteen patients (11%)
previously had a TV-ICD explantation because of lead or
device malfunction (n  8 and n  1, respectively),
infection (n  2), thrombotic occlusion (n  1), and a
complicated implantation of a TV-ICD (n  1).
General anesthesia was used in 56 patients (47%); the rest
were given local anesthesia in combination with conscious
sedation. All induced tachyarrhythmias were successfully
detected and converted into sinus rhythm. The mean rates
of the programmed conditional zone were between 190  9
and 228  11 beats/min.
Follow-up. The mean follow-up period was 18  7
months (177 patient-years). Two patients died during
follow-up, 1 because of end-stage lung carcinoma and 1
because of end-stage heart failure. The latter patient, with a
QRS duration of 100 ms, did not qualify for biventricular
pacing.
In 8 patients, a total of 9 episodes of spontaneous
sustained VT (n  4) and 36 episodes of spontaneous
ventricular fibrillation (VF) occurred (n  4). All episodes
were appropriately detected, and shock therapy was imme-
diately successful in 98% of the episodes. One patient had
an mVT that accelerated due to the shock delivered. The
episode ended spontaneously without the necessity of an-
other shock. Another patient had 6 successfully converted
episodes of mVT. The S-ICD was explanted because the
referring cardiologist preferred a transvenous system, as
ATP was deemed necessary. Of the 6 patients implanted for
secondary prevention after an episode of mVTs, no appro-
priate shocks occurred, but 1 patient had a nonsustained
episode of mVT. In total, nonsustained VT episodes were
registered in 12 patients (10%).
In 15 patients (13%) a total of 33 inappropriate shocks
occurred (Table 2). Eleven inappropriate shocks in 9 pa-
tients were due to T-wave oversensing of which 3 shocks
were prior to a software upgrade. In the other cases, T-wave
oversensing was solved by changing the sensing vector of the
S-ICD system during exercise testing (n  7) or making a
new template during exercise testing (n  1). One patient
received 15 shocks on double counting because of a newly
developed complete right bundle branch block, which was
solved by making a new template. One patient had an
inappropriate shock because of noise sensing caused by
transcutaneous electrical nerve stimulation therapy. One
patient received an inappropriate shock due to atrial flutter,
with a ventricular rate in the unconditional zone. Three
patients experienced inappropriate shocks due to myopo-
tential sensing caused by lead migration in 2 of the 3
patients. No inappropriate shocks occurred due to atrial
fibrillation or other supraventricular tachycardias in the
conditional zone.
Clinically significant ICD complications, defined as clin-
ical events requiring surgical correction or hospitalization,
occurred in 16 patients (14%). Dislocation of the subcuta-
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Initial Clinical Experience With the S-ICD November 6, 2012:1933–9neous lead occurred in 3 patients, which resulted in inap-
propriate shock therapy in 2 patients. In all cases of lead
dislocation, the parasternal part of the lead migrated 1 to 2
cm caudally. This prompted the introduction of an addi-
tional suture sleeve at xiphoid level, after which dislocation
was no longer observed. There were 2 patients who had skin
erosion at the location of the S-ICD generator requiring
surgical revision. Seven patients had an infection of the
S-ICD, requiring extraction of the device. Detailed infor-
mation about these patients is described in Table 3. At least
3 of these patients had predisposing factors for developing
infections. In 3 of these patients, an S-ICD was reimplanted
in the same anatomical position 3 months later after
treatment with antibiotics.
Inappropriate shocks and complications were more fre-
quently observed in the first 15 patients per center who were
implanted with the S-ICD than in subsequent patients
(inappropriate shocks 19% vs. 6.7%, p  0.03; complica-
ions 17% vs. 10%, p  0.10) (Fig. 1).
iscussion
his study describes the largest cohort of patients to date,
ith 177 patient-years of follow-up, who received an
ntirely S-ICD for primary or secondary prevention. All
nduced tachyarrhythmias during defibrillation threshold
esting were successfully converted. After 18 months of
ollow-up 98% of the spontaneous VT/VF events were
uccessfully converted into sinus rhythm. One patient had
n mVT, which accelerated due to initial shock therapy, but
hen had spontaneous termination. It is well known that
hock therapy from a TV-ICD can also accelerate mVTs
S-ICD Related Adverse EventsTable 2 S-ICD Related Adverse Events
Patients Episodes
Inappropriate shocks
Total number 15 (100) 33 (100)
Number pre-software upgrade 6 (40) 7 (21)
Cause
T-wave oversensing 9 (60) 11 (33)
Myopotentials 3 (20) 4 (12)
Double counting 1 (6.7) 15 (45)
Atrial flutter 1 (6.7) 2 (6.1)
TENS therapy 1 (6.7) 1 (3)
Complications
Total number 16 (14)
Cause
Lead dislodgement 3 (2.5)
Device dislodgement 1 (0.8)
Infection 7 (5.9)
Premature battery depletion 2 (1.7)
Skin erosion 2 (1.7)
Explantation because of need for ATP 1 (0.8)
Values are n (%).
ATP  antitachycardia pacing; S-ICD  subcutaneous implantable cardioverter-defibrillator;
TENS  transcutaneous electrical nerve stimulation therapy.11,12). The spontaneous termination of this arrhythmic Ch T P A
D IC P M S N S L In A R
C
M
P
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November 6, 2012:1933–9 Initial Clinical Experience With the S-ICDepisode prevented additional shocks. These results confirm
the earlier reported very reliable shock efficacy of the
S-ICD.
The decision to implant an S-ICD was mainly on the
basis of 3 selection criteria: 1) patient preference; 2) after
complications of a transvenous system; and 3) when the
physician deemed S-ICD implantation more appropriate
(e.g., because of a young age of the patient). This explains
the relative younger age of these patients and the high
percentage of patients with inherited diseases at baseline
compared with conventional ICD populations in other
studies (1,3,4). Most (89%) of these patients with inherited
diseases had a prophylactic S-ICD implantation. The mean
ejection fraction of these patients was 56%. This also
accounts for the relatively high mean LVEF in our study
population (41% in general; 38% in the primary prevention
and 50% in the secondary prevention category).
Patients with a primary as well as secondary prevention
had S-ICDs implanted. In the secondary prevention group,
6 patients had a history of mVTs. None of these 6 patients
experienced appropriate shocks. On the other hand, 4 other
patients received appropriate shocks on mVT, of which 1 of
them had 6 successfully converted episodes of mVT. The
latter patient had his S-ICD replaced by a TV-ICD to allow
ATP. The lack of ATP capabilities in the S-ICD may be a
possible limitation of the system, although this remains
debatable. Decreasing the rate of painful ICD shocks for
VT is an accepted reason to program ATP. Inappropriate
intervention for self-terminating rhythms such as nonsus-
tained VT may occur when ATP is used empirically (13).
Several studies have demonstrated that ATP terminates
around 80% of the slow and fast VTs, with acceleration rates
between 1% and 5% (13,14). Remarkably, earlier studies
testing ATP in induced VTs had lower success rates and
higher acceleration rates (15–18). Additionally, the
PAINFREE Rx II (Pacing Fast VT Reduces Shock Ther-
Figure 1 Comparison of Inappropriate Shock and Complication
Rate Between First and Later S-ICD Implants
Inappropriate shocks and complications occurred more frequently in the first
15 patients per center who were implanted with the subcutaneous implantable
cardioverter-defibrillator (S-ICD) than in subsequent patients (inappropriate
shocks 19% vs. 6.7%; complications 17% vs. 10%).apies II) trial had higher syncopal events in the ATP arm,perhaps due to acceleration of nonsustained VT by ATP
(13). Moreover, most patients with an out-of-hospital
cardiac arrest have VF (19), where ATP is not indicated.
Nevertheless, patients with frequent therapy refractory sus-
tained mVTs, although small in number, might benefit
from ATP and therefore seem less suitable for the S-ICD.
Inappropriate shocks were observed in 15 patients (13%),
comparable to the rate of inappropriate shocks in TV-ICDs
(20). Six patients experienced inappropriate shocks before
upgrading the software, which specifically aimed to reduce
the inappropriate shock rate. T-wave oversensing was the
main cause of inappropriate shock therapy before and after
the upgrade. The S-ICD has a morphology based sensing
algorithm and depends on a significant difference in the
ratio between R- and T-wave for appropriate sensing.
Before implant, in all patients a T-waveform analysis, to
screen the QRS to T-wave ratio for correct sensing, was
performed. This analysis is performed in supine and stand-
ing position during rest and therefore relatively slow heart
rate. In all patients this analysis was deemed acceptable.
During the automatic setup during implantation the device
selects the best of 3 possible vectors on the basis of this R-
to T-wave ratio and a template is made to store the QRS
morphology and R- to T-wave ratio. Usually this setup is
performed in rest. We noticed, however, that during or
shortly after exercise a different QRS to T-wave ratio
developed in 6 patients causing 8 exercise-related inappro-
priate shocks caused by T-wave oversensing. By choosing a
different sensing vector or making a new template during an
exercise test in these patients, further inappropriate shocks
were prevented. Therefore, it might be recommended to
perform the automatic setup routinely during an exercise
test, when the patient is mobilized again. Also, 1 patient
experienced inappropriate shocks due to double counting
after newly developed right bundle branch block. It would
be useful if the device would be able to create an automatic
template on a daily basis, to prevent shocks for newly
developed intraventricular conduction delay. Further analy-
sis should be done to identify patients with an S-ICD who
are at increased risk for T-wave oversensing.
In total, 14% of the patients experienced ICD-related
complications, similar to the complication rate in trans-
venous ICD trials (1,4). Three patients had lead dislocations
causing inappropriate sensing and shock therapy in 2 of
them. All dislocations were due to caudal migration of 1 to
2 cm of the parasternal part of the lead. An additional
suture sleeve was introduced to fixate the lead at the level
of the xiphoid incision. After the introduction of this suture
sleeve no lead dislocations have occurred. This study there-
fore demonstrates that the introduction of this suture
sleeve at the xiphoid level was successful in preventing
lead dislocations.
Seven patients had an infection that mandated the
removal of the device system. This relatively high infection
rate of 5.9% might partly be due to the fact that part of these
patients were at increased risk for infection: 1 was a diabetic
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the hematogenous source of the infection and 1 manipu-
lated his wound. It should be noted that because of the
novelty of the device there are no experienced implanters.
This might have led to a prolonged implantation procedure
time causing an increased infection rate, as in TV-ICDs
implantation procedure time is directly related to infection
risk (21). In most cases, infections in the S-ICD were only
skin-deep (in our study only 2 S-ICD infections were
systemic) and were therefore easily managed, whereas re-
moval of infected transvenous devices and leads are associ-
ated with a significant risk of morbidity and mortality (22).
In 3 patients, 3 months after explantation and treatment
with antibiotics, reimplantation of a new S-ICD was
successful.
Premature battery depletion occurred in 2 patients within
2 years. These 2 devices were part of a specific subset of
devices for which a field safety advisory was reported. The
risk for premature battery depletion was due to a specific
condition within an individual battery cell, as reported by
Cameron Health (23).
Skin erosion was seen in 2 patients. In 1 patient the
pocket was probably not wide enough which led to com-
plaints of pain especially during excessive movement of the
left arm. After surgical revision of the pocket this problem
was resolved. The larger generator of the S-ICD might have
led to these pocket complications. With downsizing the
S-ICD generator, pocket-related complications might be
further reduced in the future. However, it is important to
note that although the generator size of TV-ICDs has
dramatically decreased, skin erosions have not disappeared
in these patients.
The substantial implantation-related complications and
long-term complications associated with lead longevity and
subsequent risk of system extractions encountered in trans-
venous systems resulted in the development of an entirely
S-ICD. However, as we demonstrate, the subcutaneous
position of the S-ICD brought new limitations, such as
inappropriate shocks due to oversensing. One can only
speculate about the decrease in long-term complications
compared with TV-ICDs and this has to be proven in the
future in clinical trials. However, lead fractures were not
observed in 177 patient-years of follow-up, which is less
than found in TV-ICDs (24).
Moreover, an interesting observation in this Dutch expe-
rience is that relatively more inappropriate shocks and
complications occurred in the first 15 implanted patients per
center. There appears to be both a physician- and device-
related learning curve. The software upgrade, the introduc-
tion of the suture sleeve at xiphoid level at implantation to
prevent lead migration, the knowledge of preventing inap-
propriate shocks by applying vector and template changes in
some patients, and the creation of a wide enough pocket in
the left axillary region to prevent skin erosion seem to
decrease complication and inappropriate shock rates sub-
stantially. Evolving experience will hopefully solve more ofthe complexities, which arise with developing a new ICD
system.
Conclusions
This retrospective study suggests that the S-ICD is effective
in terminating ventricular arrhythmias, but it also draws
attention to some limitations due to its subcutaneous
position. Inappropriate therapy is an important issue in the
S-ICD. However, both inappropriate shocks and device-
related complications seemed to be related to a learning
curve of both the device and the physician. Our study
demonstrates that the S-ICD is a viable alternative to
conventional ICD systems in selected patients. Randomized
comparative trials with the S-ICD and TV-ICD will
further define the role of the S-ICD as an adjunctive or
primary therapy in patients at risk for sudden cardiac death.
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